

ASIRI SURGICAL HOSPITAL PLC
INTERIM FINANCIAL STATEMENT FOR THE PERIOD ENDED
31 December 2025

Asiri Surgical Hospital PLC

STATEMENT OF PROFIT OR LOSS

For the Nine Months Period Ended 31 December

	Group		Company	
	2025	2024	2025	2024
	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited
Revenue	5,850,027,128	5,345,223,941	5,270,708,330	4,787,554,674
Cost of Services	(3,296,806,744)	(3,131,088,870)	(3,063,593,162)	(2,902,619,799)
Gross Profit	2,553,220,384	2,214,135,071	2,207,115,168	1,884,934,875
Other Income	59,403,997	73,513,451	97,162,352	107,809,398
Administrative Expenses	(1,435,197,047)	(1,418,595,451)	(1,405,221,587)	(1,374,993,379)
Selling and Distribution Costs	(150,240,417)	(140,710,623)	(127,562,860)	(123,759,444)
Finance Cost	(211,558,561)	(257,776,984)	(248,883,749)	(284,670,250)
Finance Income	388,882,368	340,560,930	388,183,270	338,704,057
Profit Before Tax	1,204,510,724	811,126,395	910,792,594	548,025,257
Tax Expense	(479,713,237)	(341,923,847)	(390,815,191)	(263,002,111)
Profit for the Period	724,797,487	469,202,548	519,977,403	285,023,146
Attributable to:				
Equity holders of the parent	621,406,662	371,733,635		
Non-controlling interest	103,390,825	97,468,914		
Earnings Per Share - Basic	1.18	0.70	0.98	0.54
Dividend Per Share	0.00	0.00	0.00	0.00

STATEMENT OF COMPREHENSIVE INCOME

For the Nine Months Period Ended 31 December

	Group		Company	
	2025	2024	2025	2024
	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited	Rs. Un-audited
Profit for the Period	724,797,487	469,202,548	519,977,403	285,023,146
Other Comprehensive Income/(Loss)				
Other Comprehensive Income/(Loss) not to be reclassified to profit or loss in subsequent periods (net of tax) :				
Income / (Loss) on valuation of Financial Assets - FVOCI	-	11,146,224	-	11,146,224
	-	11,146,224	-	11,146,224
Deferred Tax on Other Comprehensive Income	-	-	-	-
Net Other Comprehensive Income/ (Loss) not to be reclassified to profit or loss in subsequent periods (net of tax)	-	11,146,224	-	11,146,224
Other Comprehensive Income/ (Loss) for the period, net of tax	-	11,146,224	-	11,146,224
Total Comprehensive Income/ (Loss) for the period, net of tax	724,797,487	480,348,772	519,977,403	296,169,370
Attributable to:				
Equity holders of the parent	621,406,662	382,879,859		
Non-controlling interest	103,390,825	97,468,914		

Asiri Surgical Hospital PLC

STATEMENT OF PROFIT OR LOSS

For the Three Months Ended 31 December

	Group		Company	
	2025	**2024**	**2025**	**2024**
	Rs. Un-audited	**Rs. Un-audited**	**Rs. Un-audited**	**Rs. Un-audited**
Revenue	1,964,151,264	1,805,764,992	1,781,679,664	1,618,389,438
Cost of Services	(1,102,921,841)	(1,050,356,270)	(1,024,607,131)	(975,123,923)
Gross Profit	861,229,423	755,408,722	757,072,533	643,265,515
Other Income	19,791,358	(3,072,475)	32,277,631	9,223,120
Administrative Expenses	(490,662,997)	(515,134,964)	(481,104,650)	(500,613,656)
Selling and Distribution Costs	(50,382,396)	(46,897,227)	(44,003,029)	(41,064,528)
Finance Cost	(69,133,873)	(84,743,910)	(82,554,384)	(96,048,942)
Finance Income	190,853,122	108,532,472	190,575,733	108,156,272
Profit Before Tax	461,694,638	214,092,619	372,263,836	122,917,781
Tax Expense	(178,590,548)	(114,413,795)	(153,068,681)	(89,328,395)
Profit for the Period	283,104,091	99,678,824	219,195,155	33,589,386
Attributable to:				
Equity holders of the parent	251,428,125	65,687,471		
Non-controlling interest	31,675,965	33,991,353		
Earnings Per Share - Basic	0.48	0.12	0.41	0.06
Dividend Per Share	0.00	0.00	0.00	0.00

STATEMENT OF COMPREHENSIVE INCOME

For the Three Months Ended 31 December

	Group		Company	
	2025 Rs. Un-audited	2024 Rs. Un-audited	2025 Rs. Un-audited	2024 Rs. Un-audited
Profit for the Period	283,104,091	99,678,824	219,195,155	33,589,386
Other Comprehensive Income/(Loss)				
Other Comprehensive Income/(Loss) not to be reclassified to profit or loss in subsequent periods (net of tax) :				
(Loss)/Gain on valuation of Financial Assets - FVOCI	-	11,146,224	-	11,146,224
Net Other Comprehensive Income not to be reclassified to profit or loss in subsequent periods (net of tax)	-	11,146,224	-	11,146,224
Other Comprehensive Income/(Loss) for the period, net of tax	-	11,146,224	-	11,146,224
Total Comprehensive Income for the period, net of tax	283,104,091	110,825,048	219,195,155	44,735,610
Attributable to:				
Equity holders of the parent	251,428,125	76,833,695		
Non-controlling interest	31,675,966	33,991,353		

STATEMENT OF FINANCIAL POSITION

Group As at 31-Mar-25 Rs. Audited	Company As at 31-Mar-25 Rs. Audited		Group As at 31-Dec-25 Rs. Un-audited	Group As at 31-Dec-24 Rs. Un-audited	Company As at 31-Dec-25 Rs. Un-audited	Company As at 31-Dec-24 Rs. Un-audited
		ASSETS				
		Non-current Assets				
5,524,084,997	5,147,839,808	Property, Plant and Equipment	5,673,144,655	5,310,259,025	5,280,864,220	4,980,396,525
17,067,993	17,067,993	Right-of-use Asset	16,892,236	21,709,490	16,892,236	21,709,490
-	226,400,000	Investment property	-	-	226,400,000	167,800,000
-	1,881,194,729	Investment in Subsidiary	-	-	1,881,194,730	33,800,104
1,979,529,017	1,979,529,017	Loans Granted to Related Parties	1,979,529,017	1,979,529,017	1,979,529,017	1,979,529,017
25,982,000	25,982,000	Non Current Assets	25,982,000	25,982,000	25,982,000	25,982,000
7,546,664,008	**9,278,013,548**		**7,695,547,908**	**7,337,479,532**	**9,410,862,202**	**7,209,217,136**
		Current Assets				
138,362,803	135,318,841	Inventories	185,556,627	171,293,772	180,787,009	166,078,448
1,315,529,766	1,170,845,045	Trade and Other Receivables	1,834,165,281	1,128,636,851	1,601,689,501	1,089,915,499
1,365,150,335	1,365,150,335	Other Current Assets	2,189,059,299	1,388,583,776	2,189,059,299	1,388,583,776
3,736,839,663	3,736,839,663	Loans Granted to Related Parties	4,007,240,161	4,467,113,741	4,007,240,161	4,467,113,741
336,399,603	57,999,515	Cash and Cash Equivalents	518,395,704	465,491,326	184,154,381	253,411,679
6,892,282,171	**6,466,153,398**		**8,734,417,072**	**7,621,119,467**	**8,162,930,351**	**7,365,103,144**
14,438,946,178	**15,744,166,946**	**Total Assets**	**16,429,964,980**	**14,958,599,000**	**17,573,792,553**	**14,574,320,280**
		EQUITY AND LIABILITIES				
1,393,327,565	1,393,327,565	Stated Capital	1,393,327,565	1,393,327,565	1,393,327,565	1,393,327,565
2,633,391,827	3,905,525,939	Other Components of Equity	2,633,391,827	2,463,002,918	3,905,525,939	2,482,980,793
2,446,864,511	2,087,751,555	Retained Earnings	3,068,271,174	3,182,910,339	2,607,728,959	2,809,253,097
6,473,583,903	**7,386,605,059**	**Share Holders' Fund**	**7,094,990,566**	**7,039,240,822**	**7,906,582,463**	**6,685,561,455**
418,760,302	-	Non-Controlling Interests	522,151,127	408,168,713	-	-
6,892,344,205	**7,386,605,059**	**Total Equity**	**7,617,141,693**	**7,447,409,535**	**7,906,582,463**	**6,685,561,455**
		Non-current Liabilities				
25,586,483	25,586,483	Lease Liability	29,651,787	-	29,651,787	-
557,668,563	557,668,563	Interest Bearing Loans and Borrowings	268,213,464	608,621,427	268,213,464	608,621,427
184,869,606	179,009,334	Employee Benefit Liability	200,795,915	161,599,570	193,839,543	156,043,386
1,259,268,154	1,771,780,071	Deferred Tax Liability	1,253,707,417	1,221,512,008	1,771,780,070	1,185,315,029
2,027,392,805	**2,534,044,451**		**1,752,368,583**	**1,991,733,004**	**2,263,484,865**	**1,949,979,842**
		Current Liabilities				
2,363,782,158	2,265,491,425	Trade and Other Payables	3,535,060,906	2,342,128,362	3,323,650,876	2,330,315,110
14,401,722	14,401,722	Dividend Payable	14,312,825	14,526,941	14,312,825	14,526,941
5,420,408	5,420,408	Lease Liability	5,420,408	901,483	5,420,408	901,483
1,842,659,723	2,314,359,723	Interest Bearing Loans and Borrowings	1,782,847,921	1,801,612,159	2,388,653,196	2,284,651,743
818,195,302	749,094,301	Tax Payable	938,433,721	685,881,233	887,308,996	633,977,424
474,749,856	474,749,856	Bank Overdraft	784,378,924	674,406,282	784,378,924	674,406,282
5,519,209,168	**5,823,517,435**		**7,060,454,704**	**5,519,456,461**	**7,403,725,225**	**5,938,778,983**
14,438,946,178	**15,744,166,946**	**Total Equity and Liabilities**	**16,429,964,980**	**14,958,599,000**	**17,573,792,553**	**14,574,320,280**
13.04	13.98	Net Assets Per Share	14.41	14.09	14.96	12.65

Sgd
…….
Mr. S.L.R Piyal
Director Finance

Sgd
…….
Mr. Ashok Pathirage
Chairman / Managing Director

Sgd
…….
Mr. Haresh Kaimal
Director

05 February 2026
Colombo

STATEMENT OF CHANGES IN EQUITY

For the Period Ended 31 December

Group

	Attributable to equity holders of parent						
	Stated Capital Rs.	FV Reserves of Financial Assets at FVOCI Rs.	Revaluation Reserves Rs.	Retained Earnings Rs.	Total Rs.	Non - Controlling Interest Rs.	Total Equity Rs.
Balance as at 01 April 2024	1,393,327,565	(237,743,562)	2,463,002,918	3,196,311,306	6,814,898,228	310,699,799	7,125,598,027
Profit for the Period	-	-	-	371,733,635	371,733,635	97,468,914	469,202,548
Other comprehensive Income	-	11,146,224	-	-	11,146,224	-	11,146,224
Total Comprehensive Income	-	11,146,224	-	371,733,635	382,879,859	97,468,914	480,348,772
Interim Dividend Paid - Ordinary Shares	-	-	-	(158,537,264)	(158,537,264)	-	(158,537,264)
Transfer to Retained Earnings		226,597,338		(226,597,338)	-	-	-
Balance as at 31 December 2024	**1,393,327,565**	-	**2,463,002,918**	**3,182,910,339**	**7,039,240,824**	**408,168,713**	**7,447,409,535**
Balance as at 01 April 2025	1,393,327,565	-	2,633,391,827	2,446,864,512	6,473,583,904	418,760,302	6,892,344,206
Profit for the Period	-	-	-	621,406,662	621,406,662	103,390,825	724,797,487
Other comprehensive Income	-	-	-	-	-	-	-
Total Comprehensive Income	-	-	-	621,406,662	621,406,662	103,390,825	724,797,487
Balance as at 31 December 2025	**1,393,327,565**	-	**2,633,391,827**	**3,068,271,174**	**7,094,990,567**	**522,151,127**	**7,617,141,693**

Company

	Stated Capital Rs.	FV Reserves of Financial Assets at FVOCI Rs.	Revaluation Reserves Rs.	Retained Earnings Rs.	Total Equity Rs.
Balance as at 01 April 2024	1,393,327,565	(237,743,562)	2,482,980,793	2,909,364,553	6,547,929,350
Profit for the Period	-	-	-	285,023,146	285,023,146
Other comprehensive Income	-	11,146,224	-	-	11,146,224
Total Comprehensive Income	-	11,146,224	-	285,023,146	296,169,370
Interim Dividend Paid - Ordinary Shares				(158,537,264)	(158,537,264)
Transfer to Retained Earnings	-	226,597,338	-	(226,597,338)	-
Balance as at 31 December 2024	**1,393,327,565**	-	**2,482,980,793**	**2,809,253,097**	**6,685,561,455**
Balance as at 01 April 2025	1,393,327,565	1,293,176,237	2,612,349,702	2,087,751,555	7,386,605,060
Profit for the Period	-	-	-	519,977,403	519,977,403
Other comprehensive Income	-	-	-	-	-
Total Comprehensive Income	-	-	-	519,977,403	519,977,403
Balance as at 31 December 2025	**1,393,327,565**	**1,293,176,237**	**2,612,349,702**	**2,607,728,959**	**7,906,582,463**

STATEMENT OF CASH FLOWS

For the Period Ended 31 December

	Group		Company	
	2025	2024	2025	2024
Cash Flows From Operating Activities	Rs.	Rs.	Rs.	Rs.
Profit Before Income Tax Expense	1,204,510,724	811,126,395	910,792,594	548,025,257
Adjustments for				
Amortization of Leasehold Assets	175,757	222,282	175,757	222,282
Depreciation	300,455,976	290,816,892	268,536,236	257,415,608
Loss on Sale of Property, Plant and Equipment	6,674	-	6,674	-
Finance Income	(388,882,368)	(340,560,930)	(388,183,270)	(338,704,057)
Finance Expense	211,558,561	257,776,984	248,883,749	284,670,250
Unrealized Foreign Currency Exchange Gain	(862,455)	(752,122)	(862,455)	(752,122)
Provision for Retirement Obligation Plan	34,107,747	21,898,184	32,870,247	20,601,689
Provision for Bad Debts	(22,792)	5,445,567	(22,792)	5,445,567
Inventory Write off	(276,455)	(1,567,269)	(276,455)	(1,567,269)
Scrip dividends received	-	(14,442,348)	-	(14,442,348)
Operating Profit Before Working Capital Changes	1,360,771,369	1,029,963,634	1,071,920,285	760,914,856
Changes in Working Capital				
(Increase)/Decrease in Inventories	(47,193,824)	41,406,697	(45,468,168)	42,372,986
(Increase)/Decrease in Trade and Other Receivables	(497,697,649)	(1,281,481,945)	(409,264,136)	(1,217,964,361)
(Increase)/Decrease in Other Current Assets	(735,247,581)	92,099,382	(735,247,581)	103,401,871
Increase/(Decrease) in Trade and Other Payables	1,171,278,748	909,662,912	1,058,159,451	909,985,645
	(108,860,306)	(238,312,954)	(131,820,434)	(162,203,858)
Cash Generated From Operations	1,251,911,062	791,650,680	940,099,850	598,710,997
Income Tax paid	(355,694,424)	(213,838,922)	(252,600,496)	(147,610,959)
Finance Costs paid	(207,493,257)	(238,380,917)	(240,046,207)	(265,274,182)
Defined Benefit Plan Costs paid	(18,181,437)	(20,220,575)	(18,040,037)	(20,220,575)
Net Cash Flows From Operating Activities	670,541,945	319,210,267	429,413,111	165,605,281
Cash Flows From/(Used in) Investing Activities				
Acquisition of Property, Plant and Equipment	(449,604,501)	(243,135,558)	(401,649,514)	(235,537,901)
Proceeds from Sale of Shares	-	270,388,572	-	270,388,572
Proceeds from Sale of Property, Plant & Equipment	82,169	-	82,169	-
Loans Granted to Related Parties	-	(17,000,000)	-	(17,000,000)
Loans Repayments from Related Parties	-	15,000,000	-	15,000,000
Finance income received	703,216	1,861,556	4,118	4,683
Loans Received from Related Parties	-	-	125,000,000	150,000,000
Net Cash Flows From Investing Activities	(448,819,116)	27,114,570	(276,563,226)	182,855,355
Cash Flows from /(Used in) Financing Activities				
Repayment of Interest Bearing Loans and Borrowings	(349,266,900)	(334,161,779)	(336,235,189)	(316,661,779)
Dividend Paid	(88,898)	(158,537,264)	(88,898)	(158,537,264)
Net Cash Flows Used in Financing Activities	(349,355,796)	(492,699,042)	(336,324,086)	(475,199,043)
Net Increase in Cash and Cash Equivalents	(127,632,967)	(146,374,205)	(183,474,202)	(126,738,407)
Cash and Cash Equivalents at the beginning of the period	(138,350,253)	(62,540,751)	(416,750,341)	(294,256,196)
Cash and Cash Equivalents at the end of the period	(265,983,221)	(208,914,956)	(600,224,543)	(420,994,603)
Cash & Cash Equivalents				
Cash and Bank Balances	518,395,704	465,491,326	184,154,381	253,411,679
Bank Overdrafts	(784,378,924)	(674,406,282)	(784,378,924)	(674,406,282)
	(265,983,220)	(208,914,956)	(600,224,543)	(420,994,603)

NOTES TO THE INTERIM FINANCIAL STATEMENTS

For the Period Ended 31 December 2025

1. Corporate Information

1.1 General

Asiri Surgical Hospital PLC ("Company") is a public limited liability Company, incorporated and domiciled in Sri Lanka and listed on the Colombo Stock Exchange. The registered office and principal place of business is located at No. 21, Kirimandala Mawatha, Colombo 5.

1.2 Date of Authorisation for Issue

The Interim Condensed Financial Statements of the Group and the Company for the period ended 31 December 2025 were authorised for issue by the Board of Directors on 05th February 2026.

2. Basis of Preparation

The interim condensed financial statements have been prepared in accordance with Sri Lanka Accounting Standard - LKAS 34 Interim Financial Reporting. These interim condensed financial statements should be read in conjunction with the annual financial statements for the year ended 31 March 2025. These financial statements provide the information as required in terms of Rule 7.4 of the Colombo Stock Exchange. The presentation and classification of the financial statements of the previous period have been amended, where relevant, for better presentation and to be comparable with those of the current period.

3. Accounting Policies

The same accounting policies and methods of computation as stated in the annual financial statements for the year ended 31 March 2025 are followed in the preparation of these Interim Condensed Financial Statements.

4. Other Information

4.1 Loans Granted to Related Parties

This includes loans granted to Asiri Hospital Holdings PLC, The Central Hospital Limited, Asiri Hospital Matara Pvt Ltd, Softlogic Retail Pvt Ltd, Asiri Central Hospital Limited, Softlogic Communications (Pvt) Ltd, Softlogic Brands (Pvt) Ltd and interest receivable thereon. The interest is charged at prevailing market interest rates for these loans.

4.2 Contingent Liabilities

A dispute has arisen with the Department of Inland Revenue with regard to the applicability of the income tax exemption for the years of assessment 2005/06 to 2014/15, in terms of the agreement entered between Asiri Surgical Hospital PLC and the Board of Investment of Sri Lanka (BOI) in 2000. With respect to the same we have received written notifications from the Tax Appeal Commission so far for the years of assessments from 2005/06 to 2013/14 and the company is assessing the provisioning requirement based on the applicable tax laws during that period. We are also in the process of initiating Legal action against these assessments in the Court of Appeal.

We also have filed a Writ application in the Court of Appeal in CA (Writ) 386/ 2016 preventing the recoverability of tax for the same matter and the judgement was delivered on 19th January 2026 dismissing the application of Asiri Surgical Hospital PLC. Since there is a litigation, in accordance with Paragraph 92 of LKAS 37, we are unable to provide further information on this and associated risks, in order not to impair the outcome and/or prejudice the Company's position in this matter.

Other than above, there are no significant changes in the nature of the contingent liabilities and contingent assets which were disclosed in the Annual Report for the year ended 31 March 2025.

4.3 Capital Expenditure Commitments

There were no material commitments outstanding as at 31 December for future capital expenditure.

4.4 Comparative Information

Where necessary comparative figures have been reclassified to conform with the current year's presentation.

4.5 Share Capital

Issued and fully paid number of Ordinary Shares as at 31 December 2025 stands at 528,457,545.

5. Event after the balance sheet

No other events have occurred since the date of the Statement of Financial Position that necessitates adjustments to/or disclosures in the Provisional Accounts.

INVESTOR INFORMATION

Market Value of Shares

The market value of an ordinary share of Asiri Surgical Hospital PLC is as follows:

	Quarter ended 31-Dec-25	Quarter ended 31-Dec-24
- Highest Market Price – Rs.	16.90	12.40
- Lowest Market Price – Rs.	13.10	10.50
- Last Traded Price – Rs.	13.70	12.00

No of Shares Representing Stated Capital

	As at 31-Dec-25	As at 31-Dec-24
No of Ordinary Shares	528,457,545	528,457,545

* Earnings & net assets per share are based on 528,457,545 shares in issue as at 31 December 2025.

Statement of Shareholding of Directors

Name of Director	As at 31-Dec-25	As at 31-Dec-24
Mr. A. K. Pathirage	-	-
Mr. H. K. Kaimal	-	-
Mr. R. Selvaskadan	-	-
Mr. G.W.D.H.U. Gunawardena	-	-
Mr. Saar Shapira	-	-
Mr. I.M. Furkan	-	-
Mr. G.D.K.L. De Silva	-	-

Major Shareholdings

Twenty Largest Shareholders	31-Dec-25 No. of Shares	%	31-Dec-24 No. of Shares	%
Asiri Hospital Holdings PLC	422,555,413	79.96	422,555,413	79.96
Mr. D.K. Subasinghe / Mrs. S.N. Subasinghe	39,014,793	7.38	39,014,806	7.38
Mr. P.P. Subasinghe	8,162,598	1.54	8,162,598	1.54
Employees Trust Fund Board	4,418,750	0.84	4,418,750	0.84
J.B. COCOSHELL Pvt Limited	2,384,677	0.45	811,360	0.15
MR. D.M. Rajapaksa / DR.MS. D.B.D. Rajapaksa	2,152,751	0.41	2,152,751	0.41
Mr. M.R. Weerasinghe (Deceased)	2,000,000	0.38	2,000,000	0.38
Mr.U. H. Palihakkara/Mrs. D.S. Palihakkara/Mr.K.D.H Palihakkara	1,352,046	0.26	1,352,046	0.26
MRS.Chandani Vishaka Ariyaratne/ MISS.B.A. Ariyaratne	1,333,333	0.25	1,333,333	0.25
Mr. M.D.N. Jayaratne	1,164,357	0.22	2,328,713	0.44
Mrs.Himali Sushama Jayaratne	1,164,356	0.22	-	0.00
Senkadagala Finance Plc/S.Gobinath	1,160,000	0.22	-	0.00
Dr. Himali Rangika Jayasekera	818,988	0.15	818,988	0.15
Mr. Mohamed Faizer Hashim	762,239	0.14	762,239	0.14
Mrs. Sithy Jazeema Badurdeen	749,999	0.14	749,999	0.14
Dr. W.M. Swarnamali Welagedara/MR. M.P.J. Senevirathne	749,999	0.14	749,999	0.14
Mr. Nagen Dayaranjan Kurukulasuriya	730,361	0.14	730,361	0.14
Mr. Godauda Pathiranage Kapilasena	722,499	0.14	722,499	0.14
Mr. Devapriya Senevirathna Epitawatta (Deceased)	666,666	0.13	666,666	0.13
Mr. Abeysiri Hemapala Munasinghe	589,564	0.11	354,677	0.07
	492,653,389	93.22	489,685,198	92.67
Shares held by the balance shareholdings	35,804,156	6.78	38,772,347	7.34
Total Issued Shares	528,457,545	100.00	528,457,545	100.00
Public Shareholding	105,902,132	20.04	105,902,132	20.04
Total Number of Public Shareholders	3,954		3,631	

The Float- adjusted market capitalization as at 31st December 2025 is Rs.1,450,869,620.65

The Company is in compliance with option 5 of the CSE Listing Rules 7.13.1 (i) (a) which requires 20% minimum public holding percentage and 500 minimum public shareholders.

CORPORATE INFORMATION

Name of the Company
Asiri Surgical Hospital PLC

Registered Office
No. 21, Kirimandala Mawatha, Colombo 05, Sri Lanka. Telephone : 011 4524400
Email : info@asiri.lk
Web : www.asirihealth.com

Legal Form
A Quoted Public Company incorporated in Sri Lanka, under the Companies Act No. 17 of 1982 with limited liability.
The Company has re-registered under the Companies Act No. 07 of 2007. An undertaking approved by the Board of Investment of Sri Lanka (BOI) under the Board of Investment of Sri Lanka Law No. 4 of 1978.

Stock Exchange Listing
The Ordinary Shares of the Company are listed with the Colombo Stock Exchange.

Company Registration Number
PQ 208

Date of Incorporation
2nd March 2000

Directors
Mr. A.K. Pathirage - Chairman/Managing Director
Mr. H. K. Kaimal - Non- Independent Non- Executive
Mr. G. W.D.U.H. Gunawardena - Non - Independent Non - Executive
Mr. R. Selvaskandan - Independent Non-Executive
Mr. S. Shapira - Independent Non- Executive
Mr. M.I. Furkan - Independent Non - Executive
Mr. G.D.K.L.D. Silva - Independent Non- Executive

Auditors
Messrs Ernst & Young (Chartered Accountants) Rotunda Towers, No. 109, Galle Road, Colombo 03.

Secretaries
Messrs Softlogic Corporate Services (Pvt) Ltd. No. 14, De Fonseka Place, Colombo 05.

Stock Code
AMSL.N0000

Banks
Commercial Bank PLC
Hatton National Bank PLC
Nations Trust Bank PLC
Sampath Bank PLC
Cargills Bank Limited
National Development Bank PLC
DFCC Bank PLC

Subsidiary Companies
Asiri AOI Cancer Centre (Private) Limited
No. 21, Kirimandala Mawatha, Colombo 05, Sri Lanka

Audit Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.D. Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets quarterly

Remuneration Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.D. Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets once a year

Nomination and Governance Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non - Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.D. Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Related Party Transactions Review Committee

Chairman
Mr. M. I. Furkan
Independent Non -executive Director, Asiri Hospital Holdings PLC

Committee Members

Mr. H K Kaimal
Non-Independent Non -executive Director, Asiri Surgical Hospital PLC

Mr. G.D.K.L.D. Silva
Independent Non -executive Director, Asiri Surgical Hospital PLC

Frequency of meetings
Committee meets quarterly